Apellis reports preliminary 2022 EMPAVELI US net sales of ~$65M; NDA and MAA submitted

Apellis Pharmaceuticals, Inc.

Preliminary unaudited 2022 US net product revenue for EMPAVELI ~$65 million.
Submitted New Drug Application to US FDA and Marketing Authorization Application to EMA for pegcetacoplan.
Appointed Dr. Caroline Baumal as Chief Medical Officer effective Q1 2023.
Completed enrollment in Phase 2 ALS study; progressed late-stage pipeline with partner Sobi.
Deployed ~100 field-based employees mid-2022 for US commercial launch.

item 5.02 item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apellis Pharmaceuticals, Inc. reported FY 2022 results: revenue $65 million.

Period: FY 2022
Revenue: $65 million
Result: preliminary results

Exact text from the filing

Caroline Baumal as Chief Medical Officer (effective Q1 2023) ~$65 million1 in U.S. net product sales Submitted sNDA for PRINCE & 48-week PEGASUS data Submitted sNDA for EMPAVELI injector Completed >800 patient years of systemic dosing2 Progressed late-stage clinical studies with partner Sobi Advanced early-stage

View on SEC.gov

Browse all earnings releases →

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-004423

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.